AMTB

AMTB is an antagonist of transient receptor potential melastatin 8 (TRPM8). It inhibits calcium influx induced by the TRPM8 agonist icilin (Cay-10137) with an IC50 value of 0.58 µM. AMTB (3 mg/kg) decreases the number of volume-induced bladder contractions in a rat model of noxious bladder distension. It also decreases the visceromotor reflex response to urinary bladder distension (ID50 = 2.42 mg/kg), indicating antinociceptive activity. AMTB inhibits the sodium channel (Nav) isoforms Nav1.1-1.8 (IC50s = 2-14.8 µM) and decreases viability of MDA-MB-231 and SK-BR-3 breast cancer cells (IC50s = ~23.7 and 17.3 µM, respectively) in a TRPM8-independent manner.Formal Name: N-(3-aminopropyl)-2-[(3-methylphenyl)methoxy]-N-(2-thienylmethyl)-benzamide, monohydrochloride. CAS Number: 926023-82-7. Molecular Formula: C23H26N2O2S . HCl. Formula Weight: 431.0. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: 100 mM, Water: 100 mM. SMILES: O=C(N(CCCN)CC1=CC=CS1)C2=CC=CC=C2OCC3=CC(C)=CC=C3.Cl. InChi Code: InChI=1S/C23H26N2O2S.ClH/c1-18-7-4-8-19(15-18)17-27-22-11-3-2-10-21(22)23(26)25(13-6-12-24)16-20-9-5-14-28-20,/h2-5,7-11,14-15H,6,12-13,16-17,24H2,1H3,1H. InChi Key: UDXGBANGPYONOK-UHFFFAOYSA-N.